The Drug Regulatory Authority of Pakistan (DRAP) has issued an urgent recall of certain batches of Amoxil Forte syrups due to safety concerns. The antibiotic, commonly prescribed for infections such as typhoid and meningitis, is being removed from hospitals, pharmacies, and distributors across the country.
According to DRAP, Amoxil Forte 250mg and Amoxil Forte 125mg syrups are affected. The recall was initiated after packaging defects were discovered, including faulty bottle caps and seals. These issues could compromise the safety and effectiveness of the medicine.
A total of 58 batches of the 250mg syrup and 111 batches of the 125mg syrup have been marked for immediate withdrawal. The problem was first reported by GlaxoSmithKline (GSK), the manufacturer of Amoxil products, prompting swift action by DRAP to protect public health.
Patients currently using the recalled syrups are advised to stop consumption and consult their healthcare providers for alternative treatments. DRAP has directed all healthcare facilities and medical distributors to identify and remove the affected batches without delay.
In addition to the Amoxil Forte recall, DRAP also ordered the market withdrawal of contraceptive tablet Famla 28F, manufactured by Zafa Pharmaceuticals. Routine testing by the Central Drugs Laboratory in Karachi found the batches to be non-compliant with quality standards.
DRAP emphasized that these actions are part of its commitment to ensure the availability of safe and effective medicines in Pakistan.
The authority urged healthcare professionals to report any suspected adverse effects and assured the public that corrective measures are being implemented to prevent future issues.
In other news read more about Surge In Heart Attacks Among Pakistani Youth Sparks Health Crisis
